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While the beneficial versus detrimental implications of the senescence-
associated secretome remain an issue of debate, time-resolved analyses of 
its composition, regulatory mechanisms, and functional consequences 
were largely missing. The dynamic activity of NOTCH is now shown to 
direct two distinct senescence phenotypes, by first promoting a pro-
senescent TGF-β1-dependent secretome, followed by a second wave of 
pro-inflammatory, senescence-clearing cytokines. 
 
 
The molecular investigation of cellular senescence has unveiled an increasingly 
complex cellular condition the central features of which include the permanent 
cessation of cell division and a massive secretory phenotype composed of a 
plethora of factors, thereby underscoring its cell-autonomous and non-cell-
autonomous implications1. Proliferating cells enter senescence in response to 
physiological cues during embryonic patterning and organogenesis, to 
pathophysiological signals related to aging or imminent malignant transformation, 
or to exogenous causes of damage like injury or cytotoxic therapies2. 
Senescence has important clinical ramifications, especially for age-related 
disorders such as arteriosclerosis, diabetes, hepatic and pulmonary fibrosis, and 
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operates as a critical barrier to cancer development as well as an effector 
principle of anticancer therapy2. 
Oncogene-induced senescence (OIS) prevents full-blown cancer formation by 
terminating the proliferative expansion of aberrant mitogen-driven, pre-malignant 
cells, and, subsequently, by promoting their clearance through immune cells 
which are attracted by components of the senescence-associated secretory 
phenotype (SASP)3. However, the simplistic view of a solely tumor-suppressive 
process is challenged when put into the context of a heterologous tissue 
composition, in which secreted factors may impinge on bystander cells in the 
tumour environment, or SASP-primed host immune cells may cross-talk with 
non-malignant cellular components at the tumour site, possibly resulting in a pro-
tumorigenic rather than a tumor-controlling net effect1. Although senescence, 
when compared to apoptosis, has always been considered a slow-onset 
response to the initiating insult, the order of events eventually leading to full-
featured senescence, and the kinetics of distinct steps of the senescence 
process have remained largely unaddressed in the field so far. 
Employing plasma membrane proteomics (PMP), time-course analyses and 
senescence-state-specific genetic targeting, Narita and colleagues report in this 
issue of Nature Cell Biology a dynamic pattern of the OIS-related secretome 
composed of two biochemically distinct and functionally opposing subsets of 
factors4. Using induction of an oncogenic Ras-G12V allele in human diploid 
fibroblasts as a model system of OIS, PMP identified the NOTCH1 receptor, 
previously implicated in replicative senescence5, as being upregulated during 
Ras-induced senescence, which was confirmed by flow cytometry in both OIS 
and DNA damage-induced senescent cells. Starting at around day 2 after 
induction of oncogenic Ras, the time when cells begin to exhibit first signs of 
senescence, the authors observed continuously increased surface expression of 
NOTCH1, reflecting the parallel development of full senescence features in the 
cells, based on a variety of senescence markers. Interestingly, although pro-
inflammatory SASP components such as IL-1α, IL-1β, IL-6 and IL-8, as well as 
matrix-degrading proteases (such as MMP1, MMP3 and MMP10), were also 
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upregulated at full senescence, TGF-β1 was transiently induced at around day 2 
to 4, coinciding with the time when the cleaved, active NOTCH1 intracellular 
domain (N1ICD) and NOTCH1 target genes such as HES1 became detectable 
(Fig. 1a). Introduction of a dominant-negative form of the N1ICD co-activator 
MAML1 (dnMAML1) to block N1ICD action abrogated TGF-β1 induction and led 
to an even stronger increase of pro-inflammatory SASP factors, thereby 
suggesting that NOTCH1 might operate as a repressor of the pro-inflammatory 
SASP. Indeed, the authors demonstrated that N1ICD was able to repress pro-
inflammatory cytokines by downregulating the transcriptional activity of their 
master regulator C/EBPβ. Conversely, enforced expression of N1ICD at day 6, 
i.e. during the later, second phase of senescence induction, when the NOTCH1 
receptor remains strongly expressed but endogenous levels of N1ICD were no 
longer detectable, resulted in enhanced TGF-β1 but lowered pro-inflammatory 
cytokine expression, thus mimicking the first wave of the senescence-associated 
secretome. Of note, whereas the actual compositions of a N1ICD/TGF-β1-
governed versus a pro-inflammatory secretome seemed to change in a dynamic 
and reciprocal fashion over time, the senescent arrest status of the cells 
appeared unaffected by the oscillating auto- and paracrine activities of these 
factors. Constitutive N1ICD expression, with or without concomitant activation of 
oncogenic Ras, triggered cellular senescence with a distinct, persistently TGF-
β1-governed secretome that largely lacked the SASP-typical pro-inflammatory 
cytokines. Importantly, the secretome of N1ICD-senescent fibroblasts, but not the 
“second-wave” secretome of Ras- or DNA damage-induced senescent cells, 
exerted a lastingly senescence-like growth arrest in normal, proliferating “target” 
cells (Fig. 1b). 
Co-culture experiments of N1ICD-senescenct with normal fibroblasts 
demonstrated that both TGF-β and NOTCH signaling became detectable in 
bystander fibroblasts as well. Because NOTCH is activated through membrane-
bound ligands, N1ICD-driven upregulation of the NOTCH target and ligand JAG1 
may account for the cell-cell contact-dependent “lateral induction” of NOTCH 
activity, which further adds to the secretome-mediated effects in adjacent target 
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cells. The underlying principles of these findings were recapitulated in vivo, 
especially in Ras-G12V-driven hepatocyte senescence in the mouse, where Ras-
positive cells and, through “lateral induction”, surrounding Ras-negative cells, 
presented as NOTCH1/HES1-positive. Senescent Ras-dnMAML1 hepatocytes, 
destined for premature inhibition of the N1ICD/TGF-β1-governed first-wave 
secretory program, and, presumably, a switch to a more pro-inflammatory type of 
SASP, disappeared faster, which correlated with an accelerated attraction of 
CD3+ T-cells, the infiltration of which into the site was possibly facilitated by 
second-wave SASP-enhanced endothelial lymphocyte adhesion. Rather 
unexpectedly, Ras-senescent hepatocytes that co-expressed N1ICD did not 
persist for extended periods of time, but quantitatively disappeared due to an 
increased rate of apoptosis. Surprisingly, it was this genotype that ultimately 
turned out to be prone to liver cancer development. 
This work has important ramifications for our understanding of OIS as a tumor-
prohibitive safeguard program reminiscent of the natural ad integrum response to 
tissue injury, where the cell-matrix defect requires acute stabilization by pro-
fibrotic secretion from regeneration-supportive senescent cells in an early phase. 
However, these senescent cells must be immunologically cleared in a 
subsequent phase before excessive scars would form, thus contributing to tissue 
homeostasis2,6. The model presented by Narita and colleagues consists of a pro-
senescent, pro-fibrotic NOTCH1/TGF-β1-governed first wave followed by a 
C/EBPβ-driven pro-inflammatory, matrix-degrading and senescence-clearing 
second wave, and resembles a (patho-)physiological two-phase tissue repair 
program that could be enlisted to counter oncogenic activation as a distinct type 
of tissue insult. It is interesting to speculate whether the induction of NOTCH1 in 
senescence may equip the cells with a latent stemness capacity that might 
eventually help to replenish a challenged tissue when the damaging stress no 
longer applies, possibly contributing to cancer formation if NOTCH signaling 
cannot be terminated (as known from activating NOTCH1 mutations in T-cell 
acute lymphoblastic leukemia7). However, such hypotheses await future 
experimental investigation. 
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The findings of Narita and colleagues give rise to many interesting questions. 
It is currently unclear, whether this reciprocal, two-secretome model is 
generalizable in terms of different senescence-inducing triggers and alternative 
tissue contexts. The regulator residing at the tip of the hierarchical signaling 
network also awaits conclusive identification, and it would be interesting to probe 
the roles of IL-1α, the inflammasome, or NOTCH1 (Ref. 8). One also wonders 
where to position NF-κB, which shares an overlapping SASP-typical set of target 
genes with C/EBPβ. 9), but unlike C/EBPβ, is positively regulated by 
NOTCH signaling, or, may actually drive NOTCH signaling through induction of 
JAG1 (refs10,11). In addition, the signal in response to which NOTCH1/N1ICD 
gets turned off again, and whether there is a feedback loop with transducers from 
the second-wave network remain unclear. 
It would also be important to address whether stressed cells would follow the 
time-dependent two-wave model in a synchronous manner, in non-engineered, 
real tissue damage scenarios or pre-neoplastic lesions in vivo. What net impact 
should one expect from two reciprocal secretomes if they co-occur in different 
phases (and strengths) within the same local environment, ultimately neutralizing 
opposing signals, for instance, towards host immune cells? And, how different 
are homotypic responses of adjacent (pre-)cancer cells as compared to 
heterologous interactions with various stroma cell types evoked by secreted 
factors or lateral induction? Only deep-phenotyping single-cell analyses such as 
multi-color flow cytometry, multiplexed in situ-imaging or “Drop-seq” 
transcriptomics will eventually be able to scan the uniformity/heterogeneity of the 
secretome state over many individual cells of distinct origins within the (pre-
)tumor site, although tracking a multitude of individual cells over time remains a 
technical challenge in vivo12.  
These open questions notwithstanding, the study by Narita and colleagues 
has succeeded in uncovering the time-dependent two-wave composition of the 
senescence-associated secretome, furthering our current understanding of the 
SASP beyond what has been generally thought to be a rather static program. 
When considering the functionally highly discriminative secretomes 
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complementing the fluctuating numbers of senescent cells at a given time, and at 
a given site due to paracrine or lateral senescence induction on one hand, and 
immune cell-mediated clearance on the other, the previously thought terminal 
and persistent senescence condition is increasingly revealed to be dynamic and 
changeable – a “moving target”. Given that the elimination of senescent cells is a 
therapeutic objective13,14, especially in cancer, the findings presented here open 
the possibility of developing treatment strategies to stabilize the beneficial side of 
the two waves, the TGF-β-governed senescence-reinforcing phase15, or to further 
exploit the repressive impact of N1ICD signaling on C/EBPβ activity in settings 
where senescent cells seem to be accountable for lasting and possibly tumor-
promoting local inflammation. 
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Legends 
Figure 1 A NOTCH1-C/EBPβ-controlled two-wave senescence secretome 
phenotype. (a) Ras-senescent cells present with two distinct secretomes: an 
early-phase (“1st wave”) NOTCH1/TGF-β-governed signaling network that 
reinforces senescence in an auto-/paracrine fashion and in neighboring cells 
(“lateral induction”) through JAG1 ligand/NOTCH1 receptor cell-cell interactions. 
A C/EBPβ-driven, largely pro-inflammatory “2nd wave” secretome is suppressed 
as long as NOTCH1 signaling is actively mediated through the N1ICD moiety. (b) 
Early-phase Ras-senescent cells, with an activated NOTCH1/TGF-β signaling 
program, may face distinct fates: if NOTCH1/N1ICD activity persists, lateral 
induction results in senescence spreading, enhanced apoptosis, and occasional 
tumor development, as these cells do not promote immune clearance due to their 
rather immunosuppressive secretome. In contrast, late-phase senescent cells 
that switched to the C/EBPβ-driven pro-inflammatory secretome bear the risk of 
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paracrine bystander growth promotion until they get cleared by host immune 
cells. A pink outline around senescent cells reflects a Ras-active status. 
 
 
